Gilead halts emergency access to COVID-19 contender remdesivir amid 'overwhelming demand'
Monday, March 23, 2020
Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has apparently overwhelmed the Big Biotech, which has temporarily stopped granting patients emergency access to remdesivir due to an “exponential increase” in requests.
No comments:
Post a Comment